Results 41 to 50 of about 16,960 (244)

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy

Frontiers in Pharmacology, 2013
The mineralocorticoid receptor (MR) antagonists PF 03882845 and eplerenone were evaluated for renal protection against aldosterone mediated renal disease in uninephrectomized Sprague Dawley (SD) rats maintained on a high salt diet and receiving ...
Stephen eOrena, Stephen eOrena, Tristan eMaurer, Rena eEudy, Rena eEudy, Li eShe, Darla eDash, Paula eLoria, Mary Ellen eBanker, Vincent eBernardo, Meera eTugnait, Carlin eOkerberg, Jessie eQian, Carine M Boustany-Kari, Carine M Boustany-Kari   +14 more
doaj   +1 more source

Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme [PDF]

, 2016
Aims We investigated the association between worsening renal function (WRF) that occurs during renin–angiotensin–aldosterone system inhibition initation and outcome in heart failure (HF) patients with preserved ejection fraction (HFPEF) and compared ...
Brenner, Clark, Damman, Damman, Damman, Hillege, Lesogor, Lewis, Lindenfeld, Massie, McAlister, McMurray, National Institute for Health and Clinical Excellence, Pfeffer, Rossignol, Rossignol, Rusinaru, Swedberg, Testani, Vardeny, Yancy, Yusuf   +21 more
core   +1 more source

Eplerenone in the Treatment of Polypoidal Choroidal Vasculopathy

Case Reports in Ophthalmology, 2015
Overactivation of mineralocorticoid receptor pathways has been implicated in the pathophysiology of central serous chorioretinopathy (CSCR). Recently, mineralocorticoid receptor antagonists such as eplerenone have demonstrated success in treating ...
Kapil G. Kapoor, Alan L. Wagner
doaj   +1 more source

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial [PDF]

, 2016
Introduction: Diabetes mellitus affects 9% of the European population and accounts for 15% of healthcare expenditure, in particular, due to excess costs related to complications.
Beige, Joachim, Currie, Gemma, Delles, Christian, Lindhardt, Morten, Mischak, Harald, Navis, Gerjan, Noutsou, Marina, Ortiz, Alberto, Persson, Frederik, Pontillo, Claudia, Rossing, Peter, Ruggenenti, Piero Luigi, Rychlik, Ivan, Spasovski, Goce, von der Leyen, Heiko   +14 more
core   +4 more sources

Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3

Graefe's Archive for Clinical and Experimental Ophthalmology, 2022
Purpose Comparing anatomic and functional efficacy and safety of primary treatment with either half-dose photodynamic therapy (PDT) or oral eplerenone, or crossover treatment in chronic central serous chorioretinopathy patients. Methods After the SPECTRA
H. M. Feenstra, E. V. van Dijk, Thomas J. van Rijssen, R. Tsonaka, R. Diederen, C. Hoyng, R. Schlingemann, C. Boon   +7 more
semanticscholar   +1 more source

Crossover to Half-dose Photodynamic Therapy or Eplerenone in Chronic Central Serous Chorioretinopathy patients (SPECS).

Ophthalmology Retina, 2022
PURPOSE Comparing the efficacy and safety of crossover treatment to half-dose photodynamic therapy (PDT) and eplerenone treatment after failure of primary treatment in chronic central serous chorioretinopathy (cCSC) patients.
MD Helena M.A. Feenstra, MD Elon H.C. van Dijk, MD Thomas J. van Rijssen, PhD Roula Tsonaka, MD Roselie M.H. Diederen, MD Reinier O. Schlingemann, M. P. Carel B. Hoyng, MD PhD Camiel J.F. Boon   +7 more
semanticscholar   +1 more source

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE

Рациональная фармакотерапия в кардиологии, 2015
The role of aldosterone in pathophysiological processes is considered. The effects of the selective antagonist of mineralocorticoid receptor eplerenone are analyzed. The advantages of eplerenone compared with spironolactone are discussed.
B. B. Gegenava, O. M. Drapkina
doaj   +3 more sources

Hepatoprotective effect of the selective mineralocorticoid receptor antagonist, eplerenone against carbon tetrachloride-induced liver injury in rats

Annals of Hepatology, 2012
Background. Eplerenone is a selective mineralocorticoid receptor (MR) antagonist, and its potential protective role in cardiovascular injury has been reported by several studies. However, whether and how this drug can ameliorate hepatic injury in rats is
Ashraf Taye, Ihab T. Abdel-Raheem
doaj   +1 more source

Oral eplerenone for the management of chronic central serous chorioretinopathy [PDF]

International Journal of Ophthalmology, 2015
AIM: To examine eplerenone (Inspra, Pfizer), a mineralocorticoid receptor antagonist, as a treatment option for chronic central serous chorioretinopathy (CSCR).
Rishi P Singh, Jonathan E Sears, Rumneek Bedi, Andrew P Schachat, Justis P Ehlers, Peter K Kaiser   +5 more
doaj   +1 more source

Differential effects of eplerenone versus amlodipine on muscle metaboreflex function in hypertensive humans

The Journal of Clinical Hypertension, 2021
Numerous studies have demonstrated that sympathetic nervous system overactivation during exercise in hypertensive rodents and humans is due, in part, to an exaggerated reflex response known as the exercise pressor reflex.
Poghni A. Peri‐Okonny, Alejandro Velasco, Hamza Lodhi, Zhongyun Wang, Debbie Arbique, Beverley Adams‐Huet, Gary Iwamoto, Jere H. Mitchell, Masaki Mizuno, Scott Smith, Wanpen Vongpatanasin   +10 more
doaj   +1 more source